Panacea resumes limited production of Cilamin 250 capsule

Drug firm Panacea Biotec today said it has resumed limited production of Cilamin 250 capsule used for treatment of Wilsons disease and rheumatoid arthritis despite shortage of the raw material for the medicine.
The company has resumed limited production of Cilamin 250 and has released limited quantities in the market, Panacea Biotec said in a filing to BSE.
"The temporary shortage is due to sudden disruption of supplies of the raw material by the supplier beyond the control of the company," it added.
The company is also in touch with office of the Drug Controller General of India for allowing imports of raw material in parallel to registration process under this emergency situation to ensure access of the medicine to the patients, Panacea Biotec said.

"We continue to work closely with existing and potential new raw material suppliers in China and India for access to raw materials in an accelerated manner," it added.
The company expects that in next 4 weeks the supplies of the drug would normalise.
Shares of Panacea Biotec today closed at Rs 110.55 per scrip on BSE, down 5.47 per cent from its previous close.